The French company Carmat announced Friday "voluntarily temporarily" the implantations of its revolutionary artificial heart Aeson "following the occurrence of a quality problem having affected some of its prostheses", according to a press release.
This suspension "will allow us to calmly analyze the problem that has arisen and draw conclusions", indicates Stéphane Piat, general manager of the company, who announced last July that he had sold the first copy of his artificial heart. .
In mid-September, she indicated that six implantations had been carried out in Germany and Italy.